Vitrolife
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar! Interim report Q1, 2026: Strong growth in Consumables and Technologies
First quarter
-
Sales of SEK 807 (842) million, an increase of 5% in local currencies and 4% decrease in SEK.
-
Sales per region, in local currencies, were -1% in EMEA, +11% in Americas and +7% in APAC.
-
Sales per product group, in local currencies were +9% in Consumables, +11% in Technologies and -1% in Genetics.
-
Gross margin increase to 59.9% (57.4).
-
Earnings before depreciation and amortisation (EBITDA) amounted to SEK 251 (257) million, resulting in an EBITDA margin of 31.1% (30.6).
-
Net income amounted to SEK 101 (100) million, resulting in earnings per share of SEK 0.74 (0.74).
-
Operating cash flow amounted to SEK 172 (69) million.
Gothenburg, April 23, 2026
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-04-2026 08:00 CET.
| Datum | 2026-04-23, kl 08:00 |
| Källa | Cision |